All Merck & Co articles – Page 2
-
Business
Sanofi and Merck & Co end vaccines partnership
Two-decade-long alliance will split by end of 2016
-
Business
Merck & Co joins hepatitis C party
New drug adds new treatment options and increases competition in premium market
-
Business
Fixing the broken antibiotics business model
With rising resistance and doomsday warnings, focus is turning to alternative economic models to boost antibiotic R&D
-
-
Business
Heptares takes on new partners for drug discovery
Firm set to receive over $1bn from research partnerships
-
Business
Merger fever sweeps pharma
The life sciences sector has been gripped by a mergers and acquisition frenzy, and it looks set to continue. But what does it mean for the industry?
-
Business
Grabbing slices of the immuno-oncology pie
Another spate of immuno-oncology dealmaking adds to fervour in pharma’s ‘hottest space’
-
Feature
Pharma queues up for checkpoint inhibitor collaborations
Combinations of different firms’ drugs seek to reap immuno-oncology’s benefits
-
Business
Alnylam accuses Dicerna of stealing trade secrets
Firm claims rights to GalNAc conjugated siRNA technology acquired from Merck & Co
-
Business
Mergers and moves trigger pharma layoffs
Shire expects to sack 500 or more employees, while Merck and GSK also wield the axe
-
-
Business
Merck & Co to buy antibiotics specialist Cubist
Pharma giant remains committed to $9.5bn deal despite key Cubist patents being invalidated by court ruling
-
Business
Bayer to sever polymer arm
German chemical giant’s exit from the materials world will help fund its crop and healthcare ambitions
-
Business
Clinical collaborations drive cancer immunotherapy
Companies race to pair up chemotherapy drugs with immune system-boosting antibodies to greatest effect in trials
-
Business
Pharma vies to unleash immune system power on cancer
Immuno-oncological drugs look set to earn billions and significantly lengthen patients’ lives
-
Business
Merck & Co bolsters hepatitis C pipeline with Idenix acquisition
Early-stage drugs complement Merck’s own developmental portfolio
-
Business
Bayer wins race to buy Merck & Co consumer care
$14bn deal will make Aspirin inventor the number two over-the-counter healthcare company
-
Business
Merck & Co doubles up on Ablynx research deal
Cancer nanobody R&D partnership could be worth €1.7 billion
-
- Previous Page
- Page1
- Page2
- Page3
- Next Page